Baidu
map

PNAS:蛋白激酶不突变也可促进前列腺癌转移

2015-12-16 佚名 生物谷

              近日,来自美国的研究人员在国际学术期刊PNAS上发表了一项最新研究进展,他们在转移性前列腺癌细胞中发现了一些野生型蛋白激酶,可能在前列腺癌进展和转移过程中发挥了重要作用。这为前列腺癌干预治疗方法的开发提供了一些新的潜在靶点。   前列腺癌是威胁男性健康的一种恶性疾病,目前急需找到治疗

             

近日,来自美国的研究人员在国际学术期刊PNAS上发表了一项最新研究进展,他们在转移性前列腺癌细胞中发现了一些野生型蛋白激酶,可能在前列腺癌进展和转移过程中发挥了重要作用。这为前列腺癌干预治疗方法的开发提供了一些新的潜在靶点。
 
前列腺癌是威胁男性健康的一种恶性疾病,目前急需找到治疗转移性前列腺癌的治疗方法。众所周知,突变导致的蛋白激酶激活在许多癌症的进展和转移过程中发挥重要作用,但是虽然转移性前列腺癌中存在大量癌基因突变,蛋白激酶的突变却非常少。一些证据表明非突变型蛋白激酶及其相关信号途径可能参与前列腺癌进展,但是这些与前列腺癌转移存在机制关联性的激酶还没有得到深入了解。
 
在这项最新研究中,研究人员利用基于质谱技术的磷酸化蛋白质组学数据结合基因表达分析,选择了超过100种可能与人类转移性前列腺癌有关的蛋白激酶进行进一步功能分析。研究人员在小鼠前列腺癌细胞中对候选激酶进行过表达,通过这种方式进行初步的体内筛选,共发现20种能够促进癌转移的野生型激酶。
 
此后,研究人员又利用人类前列腺癌细胞对这20种激酶进行了第二轮体内筛选,结果发现RAF家族的三个成员,MERTK以及NTRK2都能够促进骨转移和内脏转移的形成,这一结果得到了PET-CT和组织学分析的证实。
 
研究人员指出,这些激酶都在人类转移性去势抵抗的前列腺癌组织中存在高表达。而这些功能研究表明特定野生型蛋白激酶在促进癌症转移方面具有强大作用,也提示这些激酶或可作为治疗干预的可能靶点得到进一步研究利用。

原文出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
    2016-11-05 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
    2015-12-26 忠诚向上

    怎么样的知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
    2015-12-24 nizongzan

    越来越好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
    2015-12-24 nizongzan

    加油

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]
    2015-12-18 redcrab
  8. [GetPortalCommentsPageByObjectIdResponse(id=1855795, encodeId=6ff01855e9570, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Nov 05 18:04:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981568, encodeId=e14d198156848, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Feb 05 14:04:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48459, encodeId=9428484592e, content=怎么样的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 17:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48332, encodeId=b2ae4833266, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:30:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47402, encodeId=8f6e4e40244, content=越来越好, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47403, encodeId=41fe4e403d2, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Dec 24 07:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495935, encodeId=4078149593529, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590273, encodeId=833015902e33e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Dec 18 04:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=)]

相关资讯

Cell reports:科学家解析PKC精细结构为药物开发提供新靶点

蛋白激酶C(PKC)是通过磷酸化调节其他蛋白活性的一类蛋白激酶。这种简单的生化过程对于决定细胞存亡至关重要。如果PKC活性发生异常,会导致许多疾病的发生。在一项发表在国际学术期刊cell reports上的最新研究中,来自美国加州大学圣地亚哥分校的研究人员对PKC的精细结构进行了进一步解析,为调节PKC的活性提供了新的靶点。研究人员指出,通过理解PKC如何保持结构紧闭,我们可以寻找新的方法使其开放

Cell Metab:腺苷酸活化蛋白激酶可抑制肿瘤

  近日加拿大麦吉尔大学研究人员发现,腺苷酸活化蛋白激酶(AMPK,可调节癌细胞内的能量代谢)在抑制肿瘤细胞生长方面发挥了关键作用。AMPK是细胞的能量调节器,当细胞内的能量水平发生变化时,它就会被打开,例如在运动或禁食期间,细胞能量水平下降,此时AMPK就可帮助改善细胞代谢以提供足够能量。研究人员发现AMPK还能调节癌细胞的代谢并且能抑制肿瘤细胞的生长。   麦吉尔大学古德曼癌症研究中心助理教

J Cell Sci:蛋白激酶通过尿激酶促进前列腺癌侵袭转移

蛋白激酶D3(PKD3)虽然已被证明有助于前列腺癌细胞的生长和生存,但其在前列腺癌细胞运动中的作用仍不清楚。 近日,一项刊登在J Cell Sci杂志上的研究表明PKD2和PKD3激活核因子-κB(NF-κB)信号和促进尿激酶型纤溶酶原激活因子(uPA)的表达/激活,而后两者对前列腺癌细胞的侵袭是至关重要的。 沉默内源性PKD2或/和 PKD3的表达能显著降低前列腺癌的细胞迁移和侵袭,同时uP

Nat Methods :探测癌细胞蛋白激酶构成的新工具

近日,科学家们开发出一种能更好地识别和衡量控制癌细胞行为的重要分子(蛋白激酶),这就为癌症诊断,预测和监测工具的改善铺平了道路。 英国癌症研究中心研究人员关注于蛋白激酶,其是控制细胞各个功能的分子。这项研究发表在Nature Methods杂志上。 早期的工作表明,一系列蛋白激酶的突变或增加都与肿瘤生长有关,并且数十年来,研究人员已开发靶向药物,抑制这种活性以杀死癌细胞。迄今已批准能减少其

Baidu
map
Baidu
map
Baidu
map